Trius Therapeutics (TSRX +1.2%) comments on Congress's approval of the Prescription Drug Users...

|By:, SA News Editor

Trius Therapeutics (TSRX +1.2%) comments on Congress's approval of the Prescription Drug Users Fee Act, saying it contains key incentives for antibiotic drug developers. The Act, which is expected to be signed into law by President Obama next week, will provide drug developers with new regulatory options to aid in the development of new treatments for infections caused by drug resistant bacteria.